Institute for Global Health



Stratified Treatment OPtimisation for HCV-1: An open-label randomised controlled trial (RCT) testing biomarker-stratified short-course first-line and re-treatment direct-acting antiviral (DAA) oral treatment regimens to cure mild chronic Hepatitis C (HCV) disease

Project Summary

New treatments for hepatitis C (HCV) can be taken for shorter periods of time, with less severe side-effects compared to previous treatments (6-12 months). Almost all people are cured with 12 weeks of treatment; it is unknown what the minimum duration of treatment could be in order to achieve cure, there have been limited investigations into shorter treatments.

The protocol has been designed as a platform protocol to look at varying (intervention) 4-6 weeks vs fixed (control) 8

weeks of first-line combined Direct Acting Antiviral (DAA) treatment with or without ribavirin for patients with mono-infection with HCV or co-infection (HIV/HCV), with genotype 1a/1b and mild liver disease.

Links to other research

Other research from the UCL Centre for Clinical Research in Infection and Sexual Health

Other research from IGH on Randomised Controlled TrialsHepatitis and Treatment

Other research from IGH in the UK